This educational activity has been designed for physcians and other healthcare practitioners with an interest in pain management.
Older patients frequently have a need for pain medication for conditions such as osteoarthritis. Treating this population can be problematic because of comorbid disorders such as hypertension, diabetes mellitus, congestive heart failure, and previous or present gastropathies that require modification of the pain treatment regimen. Use of traditional NSAIDs has been associated with adverse effects related to the above mentioned comorbidities. This educational activity presents expert speakers who discuss pain management using COX-2 inhibitors and traditional NSAIDs. Additionally, case histories illustrating specfic examples of treatment strategies are provided.
Upon completion of this educational activity, the participant should be able to:
Review factors that influence the design of pain treatment strategies (e.g., extent of disease process, comorbidities).
Describe the place of COX-2 inhibitors in a multimodal pain treatment plan.
Identify appropriate monitoring strategies for the pain patient with renal impairment.
Explain how pain assessment scales can enhance effective pain management.
Gary Ruoff, MD, Activity Chairman
Clinical Professor of Family Medicine
Michigan State University
College of Medicine
D. Craig Brater, MD
Professor of Medicine, Department of Medicine
Dean, Indiana University
School of Medicine
Marc D. Cohen, MD
Professor of Medicine
Chairman, Division of Rheumatology
Mayo Medical School
Raymond Sinatra, MD, PhD
Professor of Anesthesiology
Director of Pain Service
Yale University School of Medicine
New Haven, CT
Gary Ruoff, MD, has a financial interest/relationship or affiliation in the form of: Grant/Research Support from Elan Corporation, Merck & Co., Inc.; Pfizer Inc.; Pharmacia and Upjohn Company; and Ortho-McNeil Pharmaceuticals. Consultant for Elan Corporation; Merck & Co., Inc.; Pfizer Inc., Pharmacia and Upjohn Company; and Ortho-McNeil Pharmaceuticals. Speakers’ Bureau participant with Elan Corporation; Merck & Co., Inc.; Pfizer Inc.; Pharmacia and Upjohn Company; and Ortho-McNeil Pharmaceuticals.
D. Craig Brater, MD, has a financial interest/relationship or affiliation in the form of: Consultant for AstraZeneca Pharmaceuticals; BioGen, Inc.; Forest Laboratories; Merck & Co., Inc.; Pfizer Inc.; and Pharmacia and Upjohn Company.
Marc D. Cohen, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Amgen, Inc.; Centocor; Immunex Corporation; Merck & Co., Inc.; Pfizer Inc.; and Wyeth Pharmaceuticals.
Raymond Sinatra, MD, has a financial interest/relationship or affiliation in the form of: Grant/Research Support from Merck & Co., Inc. Speakers’ Bureau participant with Merck & Company.
Made possible by an unrestricted educational grant from Merck & Co., Inc.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and Medical Communication Media. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 4.0 hour(s) in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.
The information contained in this program does not necessarily reflect the opinions or recommendations of the Postgraduate Institute for Medicine, Merck & Co., Inc., or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.